Pathstone Family Office’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$415K Buy
23,823
+11,269
+90% +$235K ﹤0.01% 1134
2023
Q2
$263K Buy
12,554
+33
+0.3% +$717 ﹤0.01% 1019
2023
Q1
$296K Sell
12,521
-14,303
-53% -$384K ﹤0.01% 919
2022
Q4
$109M Buy
26,824
+6,882
+35% +$176K 0.93% 21
2022
Q3
$471K Buy
19,942
+9,420
+90% +$284K ﹤0.01% 1099
2022
Q2
$355K Sell
10,522
-7,051
-40% -$247K 0.01% 717
2022
Q1
$614K Buy
17,573
+150
+0.9% +$5.13K 0.01% 471
2021
Q4
$531K Buy
17,423
+4,906
+39% +$160K 0.01% 540
2021
Q3
$411K Sell
12,517
-1,336
-10% -$42.7K 0.01% 581
2021
Q2
$419K Buy
+13,853
New +$456K 0.01% 536

Other funds holding OGN

Pathstone Family Office's OGN Position: Q3 2023 in Review

Pathstone Family Office increased its Organon & Co (OGN) stake by 90% in Q3 2023, buying an estimated $235K and bringing the position to 23,823 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Pathstone Family Office first reported a position in OGN in Q2 2021 and has held it in 10 quarters since. The position peaked at $109M in Q4 2022. 730 funds tracked by Wall St. Rank hold OGN as of Q3 2023.

  • Pathstone Family Office held 23,823 shares of Organon & Co worth $415K as of Q3 2023.
  • Pathstone Family Office bought 11,269 Organon & Co shares in Q3 2023, an estimated $235K.
  • Organon & Co made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1134 holding.
  • Pathstone Family Office first reported a position in Organon & Co in Q2 2021 and has held it in 10 quarters since.
  • Pathstone Family Office's Organon & Co position peaked at $109M in Q4 2022.
  • 730 funds tracked by Wall St. Rank held Organon & Co as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.